Viva Biotech Holdings
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VBIZF research report →
About the company
As an investment holding enterprise, Viva Biotech Holdings provides comprehensive drug discovery services, leveraging a structure-based approach for biotechnology and pharmaceutical clients across the globe. Their offerings encompass discovery biology, including protein expression and purification, structural biology, identification of promising drug candidates (hit discovery), bioassay development, analysis of biomolecular interactions, and pharmacokinetics. They also deliver a range of chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, preparation for purification, and computer-aided drug design (CADD), supported by advanced chemical technology platforms.
- CEO
- Chen Cheney Mao
- IPO
- 2019
- Employees
- 2,063
- HQ
- Shanghai, CN
Price Chart
- Market Cap
- $336.85M
- P/E
- 12.29
- P/S
- 1.30
- P/B
- 0.68
- EV/EBITDA
- 6.40
- Div Yield
- 0.00%
- Gross Margin
- 37.91%
- Op Margin
- 11.17%
- Net Margin
- 12.71%
- ROE
- 5.57%
- ROIC
- 2.42%
- Revenue
- $1.68B · -15.19%
- Net Income
- $214.09M · 27.97%
- EPS
- $0.10 · 27.71%
- Op Income
- $188.26M
- FCF YoY
- -51.72%
- 52W High
- $0.43
- 52W Low
- $0.13
- 50D MA
- $0.21
- 200D MA
- $0.27
- Beta
- 1.36
- Avg Volume
- 1.23K
Get TickerSpark's AI analysis on VBIZF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our VBIZF coverage
Recent articles, reports, and earnings notes.
No research on VBIZF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VBIZF report →Similar companies
Peers in the same neighborhood.